董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yehuda Reznick | 男 | Independent Director | 78 | 未披露 | 0.38 | 2026-09-25 |
| Miriam Kidron | 女 | Director | 85 | 未披露 | 未持股 | 2026-09-25 |
| Moshe Rozenbaum | 男 | External Independent Director | 45 | 未披露 | 0.57 | 2026-09-25 |
| Yonason Greenwald | 男 | Independent Director | 42 | 未披露 | 未持股 | 2026-09-25 |
| Haggai Zamir | 男 | Independent Director | 51 | 未披露 | 未持股 | 2026-09-25 |
| Avi Gabay | 男 | Director and Chair of the Board | 41 | 未披露 | 未持股 | 2026-09-25 |
| Ariel Kallner | 男 | External Director | 46 | 未披露 | 未持股 | 2026-09-25 |
| Miriam Kidron | 女 | Director | 85 | 未披露 | 0.38 | 2026-09-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rami Aviram | 男 | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | 47 | 未披露 | 未持股 | 2026-09-25 |
| Josh Hexter | 男 | Interim Chief Executive Officer and Principal Executive Officer | 56 | 未披露 | 未持股 | 2026-09-25 |
| Keith Rose | 男 | Chief Medical Officer | 64 | 未披露 | 未持股 | 2026-09-25 |
董事简历
中英对照 | 中文 | 英文- Yehuda Reznick
-
Yehuda Reznick曾于1999年至2014年担任普华永道国际有限公司成员Kesselman & Kesselman CPA的审计合伙人。在加入Kesselman & Kesselman之前，他是Shachak的税务和审计合伙人，Peer Reznick注册会计师十六年。自2019年以来，Reznick先生还担任Hiron Trade Investments & Industrial Buildings Ltd（TASE：HRON）的董事会成员。Reznick先生曾于2017年至2023年担任Bonus BioGroup Ltd（OTC：BBIXF）的董事会成员。自2026年3月起，Reznick先生还担任Lifeward Ltd.（纳斯达克：LFWD）的董事会成员。
Yehuda Reznick served as an audit partner at Kesselman & Kesselman CPA, a member of PricewaterhouseCoopers International Limited, from 1999 until 2014. Prior to joining Kesselman & Kesselman, he was a tax and audit partner at Shachak, Peer Reznick CPA for sixteen years. Since 2019, Mr. Reznick has also served on the board of directors of Hiron Trade Investments & Industrial Buildings Ltd (TASE: HRON). Mr. Reznick previously served on the board of directors of Bonus Biogroup Ltd (OTC: BBIXF) from 2017 to 2023. Since March 2026, Mr. Reznick has also served on the board of directors of Lifeward Ltd. (Nasdaq: LFWD). - Yehuda Reznick曾于1999年至2014年担任普华永道国际有限公司成员Kesselman & Kesselman CPA的审计合伙人。在加入Kesselman & Kesselman之前，他是Shachak的税务和审计合伙人，Peer Reznick注册会计师十六年。自2019年以来，Reznick先生还担任Hiron Trade Investments & Industrial Buildings Ltd（TASE：HRON）的董事会成员。Reznick先生曾于2017年至2023年担任Bonus BioGroup Ltd（OTC：BBIXF）的董事会成员。自2026年3月起，Reznick先生还担任Lifeward Ltd.（纳斯达克：LFWD）的董事会成员。
- Yehuda Reznick served as an audit partner at Kesselman & Kesselman CPA, a member of PricewaterhouseCoopers International Limited, from 1999 until 2014. Prior to joining Kesselman & Kesselman, he was a tax and audit partner at Shachak, Peer Reznick CPA for sixteen years. Since 2019, Mr. Reznick has also served on the board of directors of Hiron Trade Investments & Industrial Buildings Ltd (TASE: HRON). Mr. Reznick previously served on the board of directors of Bonus Biogroup Ltd (OTC: BBIXF) from 2017 to 2023. Since March 2026, Mr. Reznick has also served on the board of directors of Lifeward Ltd. (Nasdaq: LFWD).
- Miriam Kidron
-
Miriam Kidron自2026年3月起担任董事会成员。Kidron博士担任Oramed的首席科学官和董事，她于2006年共同创立了该公司。Kidron博士是一名药理学家和生物化学家，她在耶路撒冷希伯来大学获得了生物化学博士学位。近20年来，Kidron博士一直是以色列耶路撒冷哈达萨希伯来大学医学中心糖尿病部门的高级研究员，因其在糖尿病研究方面的工作而获得伯尔尼施兰格奖。她曾是多伦多大学医学院的客座教授，是美国、欧洲和以色列糖尿病协会的成员。Kidron博士是多项专利的指定发明人，撰写或共同撰写了大量科学出版物。
Miriam Kidron has served as a member of Board of Directors since March 2026. Dr. Kidron serves as Chief Scientific Officer and Director of Oramed, which she co founded in 2006. Dr. Kidron is a pharmacologist and biochemist, who earned her PhD in biochemistry from the Hebrew University of Jerusalem. For close to 20 years, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah Hebrew University Medical Center in Jerusalem, Israel, earning the Bern Schlanger Award for her work on diabetes research. She was formerly a visiting professor at the Medical School at the University of Toronto and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a named inventor on multiple patents and has authored or co authored a substantial number of scientific publications. - Miriam Kidron自2026年3月起担任董事会成员。Kidron博士担任Oramed的首席科学官和董事，她于2006年共同创立了该公司。Kidron博士是一名药理学家和生物化学家，她在耶路撒冷希伯来大学获得了生物化学博士学位。近20年来，Kidron博士一直是以色列耶路撒冷哈达萨希伯来大学医学中心糖尿病部门的高级研究员，因其在糖尿病研究方面的工作而获得伯尔尼施兰格奖。她曾是多伦多大学医学院的客座教授，是美国、欧洲和以色列糖尿病协会的成员。Kidron博士是多项专利的指定发明人，撰写或共同撰写了大量科学出版物。
- Miriam Kidron has served as a member of Board of Directors since March 2026. Dr. Kidron serves as Chief Scientific Officer and Director of Oramed, which she co founded in 2006. Dr. Kidron is a pharmacologist and biochemist, who earned her PhD in biochemistry from the Hebrew University of Jerusalem. For close to 20 years, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah Hebrew University Medical Center in Jerusalem, Israel, earning the Bern Schlanger Award for her work on diabetes research. She was formerly a visiting professor at the Medical School at the University of Toronto and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a named inventor on multiple patents and has authored or co authored a substantial number of scientific publications.
- Moshe Rozenbaum
-
Moshe Rozenbaum作为战略业务领导者拥有多年的经验，在金融市场、资本筹集和企业发展方面拥有深厚的专业知识。2023年5月至2025年8月，Rozenbaum先生担任公司企业发展副总裁。Rozenbaum先生自2026年3月起担任Lifeward Ltd.（纳斯达克：LFWD）的外部董事和审计委员会主席。在此之前，2019年1月至2022年6月，Rozenbaum先生担任Yedid Capital Management Inc.业务发展主管，2011年至2019年，担任Fluent Trade Technologies Ltd.的首席财务官和首席运营官，此前曾担任安永会计师事务所的高级会计师。Rozenbaum先生拥有图罗大学会计学学士学位，是一名注册会计师。
Moshe Rozenbaum has many years of experience as a strategic business leader with deep expertise in financial markets, capital raising, and corporate development. From May 2023 to August 2025, Mr. Rozenbaum served as the VP – Corporate Development of the Company. Mr. Rozenbaum has served as an external director and Chairman of the Audit Committee of Lifeward Ltd. (Nasdaq: LFWD) since March 2026. Prior to that, from January 2019 to June 2022, Mr. Rozenbaum served as the Head of Business Development for Yedid Capital Management Inc., and from 2011 to 2019, served as the Chief Financial Officer and Chief Operating Officer of Fluent Trade Technologies Ltd. and previously served as a Senior Accountant at Ernst & Young. Mr. Rozenbaum holds a B.A. in accounting from Touro University and is a Certified Public Accountant. - Moshe Rozenbaum作为战略业务领导者拥有多年的经验，在金融市场、资本筹集和企业发展方面拥有深厚的专业知识。2023年5月至2025年8月，Rozenbaum先生担任公司企业发展副总裁。Rozenbaum先生自2026年3月起担任Lifeward Ltd.（纳斯达克：LFWD）的外部董事和审计委员会主席。在此之前，2019年1月至2022年6月，Rozenbaum先生担任Yedid Capital Management Inc.业务发展主管，2011年至2019年，担任Fluent Trade Technologies Ltd.的首席财务官和首席运营官，此前曾担任安永会计师事务所的高级会计师。Rozenbaum先生拥有图罗大学会计学学士学位，是一名注册会计师。
- Moshe Rozenbaum has many years of experience as a strategic business leader with deep expertise in financial markets, capital raising, and corporate development. From May 2023 to August 2025, Mr. Rozenbaum served as the VP – Corporate Development of the Company. Mr. Rozenbaum has served as an external director and Chairman of the Audit Committee of Lifeward Ltd. (Nasdaq: LFWD) since March 2026. Prior to that, from January 2019 to June 2022, Mr. Rozenbaum served as the Head of Business Development for Yedid Capital Management Inc., and from 2011 to 2019, served as the Chief Financial Officer and Chief Operating Officer of Fluent Trade Technologies Ltd. and previously served as a Senior Accountant at Ernst & Young. Mr. Rozenbaum holds a B.A. in accounting from Touro University and is a Certified Public Accountant.
- Yonason Greenwald
-
自2012年以来，Yonason Greenwald一直担任Greenstone Property Group的创始人和首席执行官，该公司是一家房地产投资和开发公司，在迈阿密、纽约和以色列设有办事处。他负责监督公司的投资战略、资本分配、收购、发展、融资、投资者关系和运营。在他的整个职业生涯中，他领导并参与了多个资产类别的超过10亿美元的房地产交易。格林沃尔德先生在私人和公共市场拥有20多年的投资经验。除了领导绿石地产集团，他还是科技公司、熟练护理设施、老年住宅等领域的活跃天使投资人。格林沃尔德先生担任IDF寡妇和孤儿组织美国之友组织的财务主管和董事会成员。他还在Ro'im Rachok和Sharaka的董事会任职，并在科技公司Terrific Innovation Ltd的顾问委员会任职。
Yonason Greenwald has served as the founder and Chief Executive Officer of Greenstone Property Group, a real estate investment and development firm with offices in Miami, New York, and Israel, since 2012. He oversees the firm's investment strategy, capital allocation, acquisitions, development, financing, investor relations, and operations. Throughout his career, he has led and participated in more than $1 billion of real estate transactions across multiple asset classes. Mr. Greenwald has more than 20 years of investment experience across private and public markets. In addition to leading Greenstone Property Group, he is an active angel investor in technology companies, skilled nursing facilities, and senior housing. Mr. Greenwald serves as Treasurer and a member of the Board of Directors of the American Friends of the IDF Widows and Orphans Organization. He also serves on the boards of Ro'im Rachok and Sharaka and on the Advisory Board of Terrific Innovation Ltd, a technology company. - 自2012年以来，Yonason Greenwald一直担任Greenstone Property Group的创始人和首席执行官，该公司是一家房地产投资和开发公司，在迈阿密、纽约和以色列设有办事处。他负责监督公司的投资战略、资本分配、收购、发展、融资、投资者关系和运营。在他的整个职业生涯中，他领导并参与了多个资产类别的超过10亿美元的房地产交易。格林沃尔德先生在私人和公共市场拥有20多年的投资经验。除了领导绿石地产集团，他还是科技公司、熟练护理设施、老年住宅等领域的活跃天使投资人。格林沃尔德先生担任IDF寡妇和孤儿组织美国之友组织的财务主管和董事会成员。他还在Ro'im Rachok和Sharaka的董事会任职，并在科技公司Terrific Innovation Ltd的顾问委员会任职。
- Yonason Greenwald has served as the founder and Chief Executive Officer of Greenstone Property Group, a real estate investment and development firm with offices in Miami, New York, and Israel, since 2012. He oversees the firm's investment strategy, capital allocation, acquisitions, development, financing, investor relations, and operations. Throughout his career, he has led and participated in more than $1 billion of real estate transactions across multiple asset classes. Mr. Greenwald has more than 20 years of investment experience across private and public markets. In addition to leading Greenstone Property Group, he is an active angel investor in technology companies, skilled nursing facilities, and senior housing. Mr. Greenwald serves as Treasurer and a member of the Board of Directors of the American Friends of the IDF Widows and Orphans Organization. He also serves on the boards of Ro'im Rachok and Sharaka and on the Advisory Board of Terrific Innovation Ltd, a technology company.
- Haggai Zamir
-
Haggai Zamir是一位成就卓著的工业和管理工程师，在管理大型制造设施、战略运营规划和预算监督方面拥有丰富的领导经验。自2024年以来，Zamir先生一直是旅游领域的企业家和项目开发商。2021年至2023年期间，Zamir先生在Atidim Ltd.担任建筑项目经理。在此之前，Zamir先生在以色列国防军技术和维护团结束了杰出的军事生涯，以中校军衔退休。Zamir先生以这种身份管理各种制造设施，共同制定战略工作计划并监督运营、物流、采购和库存，在生产工程、运筹、信息系统和质量控制方面领导组织范围内的政策，并监督大型员工群体。此外，Zamir先生拥有重要的治理和政策主导领导经验，曾担任当地市政当局的董事会成员（社区指导委员会成员）和委员会主席。Zamir先生获得了Ariel大学工业与管理工程学士学位。
Haggai Zamir is a highly accomplished industrial and management engineer with extensive leadership experience in managing large scale manufacturing facilities, strategic operational planning, and budget oversight. Since 2024, Mr. Zamir has been an entrepreneur and project developer in the tourism sector. Between 2021 and 2023, Mr. Zamir served as a Construction Project Manager at Atidim Ltd. Prior to that, Mr. Zamir concluded a distinguished military career in the Israel Defense Forces Technology and Maintenance Corps, retiring at the rank of Lieutenant Colonel. In such capacity, Mr. Zamir managed various manufacturing facilities, co formulated strategic work plans and oversaw operations, logistics, procurement, and inventory, led organization wide policies in production engineering, operations research, information systems, and quality control, and supervised large groups of employees. Additionally, Mr. Zamir has significant governance and policy led leadership experience, having served as a Board Member (Community Steering Committee Member) and Committee Chairman for his local municipality. Mr. Zamir received a B.Sc. from Ariel University in Industrial and Management Engineering. - Haggai Zamir是一位成就卓著的工业和管理工程师，在管理大型制造设施、战略运营规划和预算监督方面拥有丰富的领导经验。自2024年以来，Zamir先生一直是旅游领域的企业家和项目开发商。2021年至2023年期间，Zamir先生在Atidim Ltd.担任建筑项目经理。在此之前，Zamir先生在以色列国防军技术和维护团结束了杰出的军事生涯，以中校军衔退休。Zamir先生以这种身份管理各种制造设施，共同制定战略工作计划并监督运营、物流、采购和库存，在生产工程、运筹、信息系统和质量控制方面领导组织范围内的政策，并监督大型员工群体。此外，Zamir先生拥有重要的治理和政策主导领导经验，曾担任当地市政当局的董事会成员（社区指导委员会成员）和委员会主席。Zamir先生获得了Ariel大学工业与管理工程学士学位。
- Haggai Zamir is a highly accomplished industrial and management engineer with extensive leadership experience in managing large scale manufacturing facilities, strategic operational planning, and budget oversight. Since 2024, Mr. Zamir has been an entrepreneur and project developer in the tourism sector. Between 2021 and 2023, Mr. Zamir served as a Construction Project Manager at Atidim Ltd. Prior to that, Mr. Zamir concluded a distinguished military career in the Israel Defense Forces Technology and Maintenance Corps, retiring at the rank of Lieutenant Colonel. In such capacity, Mr. Zamir managed various manufacturing facilities, co formulated strategic work plans and oversaw operations, logistics, procurement, and inventory, led organization wide policies in production engineering, operations research, information systems, and quality control, and supervised large groups of employees. Additionally, Mr. Zamir has significant governance and policy led leadership experience, having served as a Board Member (Community Steering Committee Member) and Committee Chairman for his local municipality. Mr. Zamir received a B.Sc. from Ariel University in Industrial and Management Engineering.
- Avi Gabay
-
Avi Gabay是一位经验丰富的财务主管、注册会计师和律师，拥有丰富的上市公司财务、公司治理和资本市场经验。Gabay先生自2024年6月起担任Oramed及其全资以色列子公司Oramed Ltd.的首席财务官、财务主管和秘书，此前曾于2019年6月至2021年担任Oramed的首席财务官。从2023年到2024年6月，Gabay先生在BiomX Inc.担任临时首席财务官，从2021年到2023年，他在Oravax Inc.（Oravax Inc.）担任首席财务官，Oravax Inc.是Oramed的一家拥有多数股权的子公司。此前，Gabay先生曾于2015年至2019年担任OrCam Technologies Ltd.的财务副总裁。Gabay先生目前担任Sade Real Estate Y.S Ltd.（TASE：SADE）的董事，他是审计和薪酬委员会的成员。Gabay先生以优异成绩获得特拉维夫大学法律和会计学学士学位，并获得赖希曼大学医疗保健创新MBA学位。以色列注册会计师，Israel Bar协会会员。
Avi Gabay is an experienced financial executive, certified public accountant and attorney with extensive public company finance, corporate governance and capital markets experience. Mr. Gabay has served as Chief Financial Officer, Treasurer and Secretary of Oramed and its wholly owned Israeli subsidiary, Oramed Ltd., since June 2024, having previously served as Chief Financial Officer of Oramed from June 2019 to 2021. From 2023 until June 2024, Mr. Gabay served as interim Chief Financial Officer of BiomX Inc., and from 2021 to 2023, he served as Chief Financial Officer of Oravax Inc., a majority owned subsidiary of Oramed. Previously, Mr. Gabay served as Vice President of Finance at OrCam Technologies Ltd. from 2015 to 2019. Mr. Gabay currently serves as a director of Sade Real Estate Y.S Ltd. (TASE: SADE), where he is a member of the audit and compensation committees. Mr. Gabay received a bachelor's degree in law and accounting, magna cum laude, from Tel Aviv University and an MBA in Health Care Innovation from Reichman University. He is a certified public accountant in Israel and a member of the Israel Bar Association. - Avi Gabay是一位经验丰富的财务主管、注册会计师和律师，拥有丰富的上市公司财务、公司治理和资本市场经验。Gabay先生自2024年6月起担任Oramed及其全资以色列子公司Oramed Ltd.的首席财务官、财务主管和秘书，此前曾于2019年6月至2021年担任Oramed的首席财务官。从2023年到2024年6月，Gabay先生在BiomX Inc.担任临时首席财务官，从2021年到2023年，他在Oravax Inc.（Oravax Inc.）担任首席财务官，Oravax Inc.是Oramed的一家拥有多数股权的子公司。此前，Gabay先生曾于2015年至2019年担任OrCam Technologies Ltd.的财务副总裁。Gabay先生目前担任Sade Real Estate Y.S Ltd.（TASE：SADE）的董事，他是审计和薪酬委员会的成员。Gabay先生以优异成绩获得特拉维夫大学法律和会计学学士学位，并获得赖希曼大学医疗保健创新MBA学位。以色列注册会计师，Israel Bar协会会员。
- Avi Gabay is an experienced financial executive, certified public accountant and attorney with extensive public company finance, corporate governance and capital markets experience. Mr. Gabay has served as Chief Financial Officer, Treasurer and Secretary of Oramed and its wholly owned Israeli subsidiary, Oramed Ltd., since June 2024, having previously served as Chief Financial Officer of Oramed from June 2019 to 2021. From 2023 until June 2024, Mr. Gabay served as interim Chief Financial Officer of BiomX Inc., and from 2021 to 2023, he served as Chief Financial Officer of Oravax Inc., a majority owned subsidiary of Oramed. Previously, Mr. Gabay served as Vice President of Finance at OrCam Technologies Ltd. from 2015 to 2019. Mr. Gabay currently serves as a director of Sade Real Estate Y.S Ltd. (TASE: SADE), where he is a member of the audit and compensation committees. Mr. Gabay received a bachelor's degree in law and accounting, magna cum laude, from Tel Aviv University and an MBA in Health Care Innovation from Reichman University. He is a certified public accountant in Israel and a member of the Israel Bar Association.
- Ariel Kallner
-
阿里尔·卡尔纳（Ariel Kallner）自2022年起担任以色列国家立法机构以色列议会议员。他目前的任期预计将于2026年11月10日结束。作为以色列议会议员，卡尔纳先生一直负责立法、议会监督、委员会工作、国际议会关系、公共政策和选区代表。他还曾担任以色列议会驻欧洲议会代表团团长、打击毒品、酒精和毒瘾委员会主席，以及包括外交和国防委员会和国家安全委员会在内的议会委员会成员。在担任以色列议会服务之前，Kallner先生曾于2021年至2022年担任以色列造船厂集团的业务发展顾问。他还拥有约12年的国际高科技项目管理经验。Kallner先生拥有以色列理工学院工业工程和管理学士学位和海法大学MBA学位。
Ariel Kallner has served as a Member of the Knesset, Israel's national legislature, since 2022. His current term is expected to end on November 10, 2026. In his role as a Member of Knesset, Mr. Kallner has been responsible for legislation, parliamentary oversight, committee work, international parliamentary relations, public policy and constituency representation. He has also served as Head of the Knesset Delegation to the European Parliament, Chair of the Committee for the Fight against Drugs, Alcohol and Addictions, and a member of parliamentary committees, including the Foreign Affairs and Defense Committee and the National Security Committee. Prior to his current Knesset service, Mr. Kallner served as a Business Development Advisor to Israel Shipyards Group from 2021 to 2022. He also has approximately 12 years of project management experience in international high tech. Mr. Kallner holds a B.Sc. in Industrial Engineering and Management from the Technion – Israel Institute of Technology and an MBA from the University of Haifa. - 阿里尔·卡尔纳（Ariel Kallner）自2022年起担任以色列国家立法机构以色列议会议员。他目前的任期预计将于2026年11月10日结束。作为以色列议会议员，卡尔纳先生一直负责立法、议会监督、委员会工作、国际议会关系、公共政策和选区代表。他还曾担任以色列议会驻欧洲议会代表团团长、打击毒品、酒精和毒瘾委员会主席，以及包括外交和国防委员会和国家安全委员会在内的议会委员会成员。在担任以色列议会服务之前，Kallner先生曾于2021年至2022年担任以色列造船厂集团的业务发展顾问。他还拥有约12年的国际高科技项目管理经验。Kallner先生拥有以色列理工学院工业工程和管理学士学位和海法大学MBA学位。
- Ariel Kallner has served as a Member of the Knesset, Israel's national legislature, since 2022. His current term is expected to end on November 10, 2026. In his role as a Member of Knesset, Mr. Kallner has been responsible for legislation, parliamentary oversight, committee work, international parliamentary relations, public policy and constituency representation. He has also served as Head of the Knesset Delegation to the European Parliament, Chair of the Committee for the Fight against Drugs, Alcohol and Addictions, and a member of parliamentary committees, including the Foreign Affairs and Defense Committee and the National Security Committee. Prior to his current Knesset service, Mr. Kallner served as a Business Development Advisor to Israel Shipyards Group from 2021 to 2022. He also has approximately 12 years of project management experience in international high tech. Mr. Kallner holds a B.Sc. in Industrial Engineering and Management from the Technion – Israel Institute of Technology and an MBA from the University of Haifa.
- Miriam Kidron
-
Miriam Kidron， 2006年3月被任命为首席科学官兼董事。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷Hadassah University Hospital糖尿病部门的高级研究员。Kidron博士曾是多伦多大学（加拿大）医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。她是Bern Schlanger奖的获得者。
Miriam Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award. Since March 2026, Dr. Kidron has served as a director of Lifeward Ltd. (Nasdaq: LFWD). - Miriam Kidron， 2006年3月被任命为首席科学官兼董事。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷Hadassah University Hospital糖尿病部门的高级研究员。Kidron博士曾是多伦多大学（加拿大）医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。她是Bern Schlanger奖的获得者。
- Miriam Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award. Since March 2026, Dr. Kidron has served as a director of Lifeward Ltd. (Nasdaq: LFWD).
高管简历
中英对照 | 中文 | 英文- Rami Aviram
Rami Aviram自2024年8月起担任Beewise Technologies Ltd.的首席财务官。此前，他于2018年至2024年担任ENDIMED Medical Ltd.的首席财务官，并于2012年至2018年在Syneron Candela Ltd.担任高级财务领导职务。Aviram先生是一名注册会计师，拥有海法大学信息系统和经济学学士学位和经济学硕士学位。
Rami Aviram has served as Chief Financial Officer of Beewise Technologies Ltd. since August 2024. Previously, he served as Chief Financial Officer of ENDYMED Medical Ltd. from 2018 to 2024 and held senior finance leadership positions at Syneron Candela Ltd. from 2012 to 2018. Mr. Aviram is a certified public accountant and holds a B.Sc. in Information Systems and Economics and an M.A. in Economics from the University of Haifa.- Rami Aviram自2024年8月起担任Beewise Technologies Ltd.的首席财务官。此前，他于2018年至2024年担任ENDIMED Medical Ltd.的首席财务官，并于2012年至2018年在Syneron Candela Ltd.担任高级财务领导职务。Aviram先生是一名注册会计师，拥有海法大学信息系统和经济学学士学位和经济学硕士学位。
- Rami Aviram has served as Chief Financial Officer of Beewise Technologies Ltd. since August 2024. Previously, he served as Chief Financial Officer of ENDYMED Medical Ltd. from 2018 to 2024 and held senior finance leadership positions at Syneron Candela Ltd. from 2012 to 2018. Mr. Aviram is a certified public accountant and holds a B.Sc. in Information Systems and Economics and an M.A. in Economics from the University of Haifa.
- Josh Hexter
Josh Hexter自2026年9月起担任公司临时首席执行官。Hexter先生自2019年9月起担任Oramed的首席运营和业务官。在被任命为临时首席执行官后，Hexter先生继续在Oramed担任该职位，任职人数大幅减少，预计职责约占其先前在Oramed职责的5%。2018年11月至2019年9月，Hexter先生担任Brainsway Ltd.的首席商务官。2010年1月至2013年4月，他在BioLineRx Ltd.担任Corporate in Licensing执行董事。Hexter先生此前还创立并担任Biosensor Systems Design的首席执行官。Hexter先生拥有威斯康星大学的学士学位和波士顿大学的商学硕士学位。
Josh Hexter has served as the company's Interim Chief Executive Officer since September 2026. Mr. Hexter has served as Chief Operating and Business Officer of Oramed since September 2019. Following his appointment as Interim Chief Executive Officer, Mr. Hexter has continued to serve in that position at Oramed in a substantially reduced capacity, with responsibilities expected to represent approximately 5% of his prior responsibilities at Oramed. From November 2018 to September 2019, Mr. Hexter served as Chief Business Officer of BrainsWay Ltd. From January 2010 to April 2013, he served as Executive Director of Corporate In Licensing at BioLineRx Ltd. Mr. Hexter also previously founded and served as Chief Executive Officer of Biosensor Systems Design. Mr. Hexter holds a B.A. from the University of Wisconsin and a master's degree in business from Boston University.- Josh Hexter自2026年9月起担任公司临时首席执行官。Hexter先生自2019年9月起担任Oramed的首席运营和业务官。在被任命为临时首席执行官后，Hexter先生继续在Oramed担任该职位，任职人数大幅减少，预计职责约占其先前在Oramed职责的5%。2018年11月至2019年9月，Hexter先生担任Brainsway Ltd.的首席商务官。2010年1月至2013年4月，他在BioLineRx Ltd.担任Corporate in Licensing执行董事。Hexter先生此前还创立并担任Biosensor Systems Design的首席执行官。Hexter先生拥有威斯康星大学的学士学位和波士顿大学的商学硕士学位。
- Josh Hexter has served as the company's Interim Chief Executive Officer since September 2026. Mr. Hexter has served as Chief Operating and Business Officer of Oramed since September 2019. Following his appointment as Interim Chief Executive Officer, Mr. Hexter has continued to serve in that position at Oramed in a substantially reduced capacity, with responsibilities expected to represent approximately 5% of his prior responsibilities at Oramed. From November 2018 to September 2019, Mr. Hexter served as Chief Business Officer of BrainsWay Ltd. From January 2010 to April 2013, he served as Executive Director of Corporate In Licensing at BioLineRx Ltd. Mr. Hexter also previously founded and served as Chief Executive Officer of Biosensor Systems Design. Mr. Hexter holds a B.A. from the University of Wisconsin and a master's degree in business from Boston University.
- Keith Rose
基斯·罗斯自2026年5月起担任公司首席医疗官。在被任命为首席医疗官之前，罗斯博士自2023年12月起担任医疗总监和医疗事务副总裁，自2023年3月起担任医疗事务总监。在加入Lifeward之前，Dr. Rose曾于2021年11月至2023年6月在Biocodex Inc.担任医疗事务总监以及健康经济学与结果和医疗有效性总监。Rose博士此前曾在Novocure公司担任首席临床研究科学家和区域经理。Hope Network面向儿童和成人的神经康复服务的医疗总监，以及多家住院康复医院的医疗总监。Rose博士在乔治华盛顿大学医学院和Health Sciences获得医学学位，并在贝勒医学院完成了物理医学与康复以及儿科医学的住院治疗。罗斯医生持有密歇根州颁发的现役医疗执照。
Keith Rose has served as the company's Chief Medical Officer since May 2026. Before his appointment as Chief Medical Officer, Dr. Rose served as Medical Director and Vice President of Medical Affairs since December 2023 and as Director, Medical Affairs since March 2023. Prior to joining Lifeward, Dr. Rose served as Medical Director, Medical Affairs and Director, Health Economics & Outcomes and Medical Effectiveness at Biocodex Inc. from November 2021 to June 2023. Dr. Rose previously served as Lead Clinical Research Scientist and Regional Manager at Novocure, Inc. Medical Director of Hope Network's neurorehabilitation services for children and adults, and Medical Director for multiple inpatient rehabilitation hospitals. Dr. Rose received his medical degree from the George Washington University School of Medicine and Health Sciences and completed residencies in Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine. Dr. Rose holds an active medical license issued by the State of Michigan.- 基斯·罗斯自2026年5月起担任公司首席医疗官。在被任命为首席医疗官之前，罗斯博士自2023年12月起担任医疗总监和医疗事务副总裁，自2023年3月起担任医疗事务总监。在加入Lifeward之前，Dr. Rose曾于2021年11月至2023年6月在Biocodex Inc.担任医疗事务总监以及健康经济学与结果和医疗有效性总监。Rose博士此前曾在Novocure公司担任首席临床研究科学家和区域经理。Hope Network面向儿童和成人的神经康复服务的医疗总监，以及多家住院康复医院的医疗总监。Rose博士在乔治华盛顿大学医学院和Health Sciences获得医学学位，并在贝勒医学院完成了物理医学与康复以及儿科医学的住院治疗。罗斯医生持有密歇根州颁发的现役医疗执照。
- Keith Rose has served as the company's Chief Medical Officer since May 2026. Before his appointment as Chief Medical Officer, Dr. Rose served as Medical Director and Vice President of Medical Affairs since December 2023 and as Director, Medical Affairs since March 2023. Prior to joining Lifeward, Dr. Rose served as Medical Director, Medical Affairs and Director, Health Economics & Outcomes and Medical Effectiveness at Biocodex Inc. from November 2021 to June 2023. Dr. Rose previously served as Lead Clinical Research Scientist and Regional Manager at Novocure, Inc. Medical Director of Hope Network's neurorehabilitation services for children and adults, and Medical Director for multiple inpatient rehabilitation hospitals. Dr. Rose received his medical degree from the George Washington University School of Medicine and Health Sciences and completed residencies in Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine. Dr. Rose holds an active medical license issued by the State of Michigan.